Nantero Announces Licensing to Alpha Szenszor To Develop Nanotube Based Infectious Disease Detectors For Diseases Including HIV

Nantero, Inc., a nanotechnology company using carbon nanotubes for the development of next-generation semiconductor devices, has provided license rights for biomedical sensors to Alpha Szenszor, Inc., a newly-formed company also based in Woburn, Massachusetts. Alpha Szenszor is developing a suite of sensor products in the medical field, including portable and cost-effective detectors for infectious diseases such as HIV. Alpha Szenszor’s co-founders include Steve Lerner, an industry veteran with over 28 years of product development and industrialization experience, and Professor Charles Lieber of Harvard University, world-renowned expert in the field of nanobio sensors.

Nantero’s intellectual property includes over 100 patent applications, of which over 25 have already been granted. This intellectual property portfolio is centered around the use of carbon nanotubes in mass manufacturing environments to make a variety of products, including Nantero’s NRAM™, a high-density nonvolatile random access memory device. In addition to its work developing NRAM, Nantero is actively licensing its intellectual property portfolio to both startups and established companies for the development of other products that incorporate carbon nanotubes.

Alpha Szenszor is developing a biomedical sensor platform for applications in the field of disease diagnostics and personalized medicine. These products will allow testing of a wide range of diseases such as Cold and Flu, Cancer, Heart Disease, Sexually Transmitted Infections, Food Contamination, and the presence of other life threatening disorders. Alpha Szenszor technology will eliminate the costly and time consuming procedures associated with current diagnostics technology.

Steve Lerner, CEO and Co-Founder of Alpha Szenszor, said, “With our world-class team combining experts in health care, semiconductor processing, and Nantero’s scalable carbon nanotube technology, we are poised to bring revolutionary products to market in a very short time frame. We will enable portable disease testing that would be available through local pharmacies and allow anyone to test themselves with total privacy and at a low cost. When placed in the hands of the primary care physicians, we envision our technology becoming part of every patient check-up.”

Professor Charles Lieber, Co-Founder of Alpha Szenszor, added, “The Nantero technology provides a highly industrialized platform through which my years of work may be applied to facilitate this revolution in global health care.”

Greg Schmergel, CEO and Co-Founder of Nantero noted “Nantero is approached frequently for licenses to its intellectual property for various fields of use, and we have to pick carefully the right partners who have the capability to bring products to market that will add substantial value to their customers. We believe Alpha Szenszor is such a partner and look forward to working with them.” 

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit